Societe Generale Reiterates €117.00 Price Target for Bayer AG (BAYN)

Bayer AG (FRA:BAYN) has been given a €117.00 ($136.05) price target by equities research analysts at Societe Generale in a research note issued on Tuesday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Societe Generale’s target price points to a potential upside of 7.49% from the stock’s previous close.

A number of other equities research analysts have also weighed in on BAYN. J P Morgan Chase & Co set a €125.00 ($145.35) price target on shares of Bayer AG and gave the company a “buy” rating in a report on Tuesday, July 18th. Goldman Sachs Group, Inc. (The) set a €125.00 ($145.35) price target on shares of Bayer AG and gave the company a “buy” rating in a report on Monday, July 24th. Citigroup Inc. set a €128.00 ($148.84) price target on shares of Bayer AG and gave the company a “buy” rating in a report on Monday, July 24th. Deutsche Bank AG set a €124.00 ($144.19) price target on shares of Bayer AG and gave the company a “buy” rating in a report on Monday, July 24th. Finally, Commerzbank Ag set a €126.00 ($146.51) price target on shares of Bayer AG and gave the company a “buy” rating in a report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of €122.33 ($142.25).

Bayer AG (FRA:BAYN) traded up €0.20 ($0.23) on Tuesday, reaching €108.85 ($126.57). 1,104,667 shares of the company were exchanged. Bayer AG has a 1-year low of €86.06 ($100.07) and a 1-year high of €123.82 ($143.98).

WARNING: This report was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/11/14/societe-generale-reiterates-117-00-price-target-for-bayer-ag-bayn.html.

Bayer AG Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer AG (FRA:BAYN)

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply